PIK3CA and cancer: In fact, a study of TTKi CFI-402257 revealed no correlation between treatment response and key cancer-associated mutations (e.g., in APC, BRAF, CDKN2A, PIK3CA, RAS, and TP53) or cell doubling time across a panel of cancer cell lines (6).